Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3008 |
Name | invasive ductal carcinoma |
Definition | A breast ductal carcinoma that is characterized by infiltration into the fibrous or fatty tissue of the breast outside of the duct where it originated. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3005 |
Path | disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer breast carcinoma breast ductal carcinoma invasive ductal carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR2 V564L | Pemigatinib | invasive ductal carcinoma | predicted - resistant | detail... |
ATM inact mut | Durvalumab + Olaparib | invasive ductal carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02779855 | Phase Ib/II | Paclitaxel + Talimogene laherparepvec | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03356860 | Phase Ib/II | Cyclophosphamide + Durvalumab + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel | Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE) | Completed | BEL | 0 |
NCT03596073 | Phase I | Calcipotriene | Topical Calcipotriene Treatment for Breast Cancer Immunoprevention | Terminated | USA | 0 |
NCT03725059 | Phase III | Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Epirubicin + Paclitaxel Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | Active, not recruiting | USA | POL | NZL | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 10 |
NCT04129216 | Phase II | Letrozole Tamoxifen Exemestane | The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer | Completed | USA | 0 |
NCT04781725 | Phase II | INT230-6 | Intratumoral INT230-6 in Breast Cancer | Unknown status | CAN | 0 |
NCT06139107 | Phase I | Abemaciclib + Letrozole | RADIANT: Pre-op Radiation With Abemaciclib and Letrozole | Recruiting | USA | 0 |